Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review - Takeaways - MDSpire

Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review

Share

1

Immune checkpoint inhibitors (ICIs) enhance progression-free survival and overall survival across various cancer types.
2

ICIs are associated with immune-related adverse events (irAEs) affecting multiple organ systems, requiring careful management.
3

Biomarkers like PD-L1 expression and tumor mutational burden (TMB) predict ICI response but not irAE risk.
4

Combination strategies involving ICIs show improved efficacy but increase the risk of toxicity compared to monotherapy.
5

Future research should focus on optimizing patient selection, toxicity management, and identifying new predictive biomarkers.

Frontiers In Oncology

Frontiers In Oncology

Frontiers In Medicine

Frontiers In Medicine

1